<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937547</url>
  </required_header>
  <id_info>
    <org_study_id>CERVICAL CANCER AND HPV</org_study_id>
    <nct_id>NCT00937547</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus Infection and Virus Genotyping in Uterine Cervix Cancer in Venezuela</brief_title>
  <acronym>HPI</acronym>
  <official_title>Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Oncologico Luis Razetti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Oncologico Luis Razetti</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Hypothesis:

           If high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer
           worldwide, the genotypes associated with cervical cancer in Venezuela would be the same
           types found in other countries.

        2. Objectives:

      Primary objective:

      The objective of this investigation is to determine the presence and genotypes of HVP
      infection in cervical intraepithelial neoplasia grade 2/3 (CIN 2/3), and Stage I cervical
      epidermoid carcinoma and cervical adenocarcinoma.

      Specific objectives:

      To establish the presence of HPV in cervical cancer patients in Venezuela by geographic
      distribution.

      To establish which HPV types are linked with cervical cancer in Venezuela by geographic
      distribution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Venezuela, cervical cancer is the second leading cause of cancer mortality in women. In
      developed countries, although it is not the first cause of cancer mortality, occupies a
      remarkable place in the neoplastic pathology (Cannistra, 1996; Dey, 1998).

      Human Papilloma Virus (HPV) is involved in the development of cervical cancer, specially
      oncogenic types 16 and 18 (Koskela, 2000; Markowska, 1999).

      To date, it is still unknown which HPV types are more frequent in Venezuela. Several studies
      made in this country concluded that HPV 16 is the predominant type in cervical pathology
      (Graterol 2006, Correnti 1997, Muñoz 2003), but there has not been performed a HVP genotyping
      to detect all the types involved in patients with cervical cancer. Neither has been establish
      which HPV types are more frequently involved in genital warts in Venezuela.

      The goal of this investigation is perform a genotypification of HPV in cervical cancer and
      cervical intraepithelial neoplasia 2 and 3 in Venezuela to determine which types are more
      frequently related to this disease in our country.

      4. STUDY DESIGN:

      4.1. Collection of cervical samples:

      1. Previous ethics committee approval (Instituto Venezolano de Investigaciones Cientificas
      and Instituto de Oncología Luis Razetti), we are going to collect paraffin blocks of 300
      patients with histological diagnosis of CIN 2-3 or Stage I cervical cancer.

      The samples will be obtained from archives of the Pathology Units of the following medical
      centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad
      Central de Venezuela(Caracas), Hospital Oncológico Pérez Carreño (Valencia), Maracaibo,
      Barquisimeto, Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.

      Inclusion criteria:

        1. Paraffin blocks with CIN 2/3, and Stage I cervical cancer biopsies obtained between 2001
           and 2011.

        2. Properly blocks identification in order to obtain personal and clinical patient
           information.

      4.2. Molecular biology procedures:

        1. Histologically handling of tissue: previous identification of pathologic lesions as
           described in inclusion criteria by an expert pathologist (sample with lesion but without
           necrosis), the paraffin block will be cut into 5 to 7 µm slides with new blades and
           gloves for each cut. It will be obtain 1 slides that will be distributed as follows: one
           sample will be send to Laboratorio de Virología Molecular del Instituto Venezolano de
           Investigaciones Científicas; the remained sample will be kept for further evaluation if
           is necessary. Each slide will be placed in a proper container and will be identified by
           a serial number in order to preserve patient intimacy and avoid biased results.

        2. Deparaffinisation as described in Coombs 1999.

        3. Tissue digestion, DNA extraction and precipitation as described in Gravitt 2000.

        4. HPV genotyping will be detected by INNOLiPA system. The results will be correlated with
           clinical information.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HPV Identification</measure>
    <time_frame>6 months</time_frame>
    <description>HPV distribution was identified in CIN2, CIN3 and invasive cervical cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 16</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 18</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 18.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 31</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 31.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 33</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 33.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 45</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 45.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 58</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 58.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HPV Type 51</measure>
    <time_frame>6 months</time_frame>
    <description>Number of biopsies positive to HPV 51.</description>
  </primary_outcome>
  <enrollment type="Actual">329</enrollment>
  <condition>Cervical Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      4.1. Collection of cervical samples:

      1. Previous ethics committe approval (Instituto Venezolano de Investigaciones Cientificas and
      Instituto de Oncología Luis Razetti), we are going to collect paraffin bloks of 300 patients
      with hystologic diagnosis of CIN 2/3 or Stage I cervical cancer.

      The samples will be obtained from archives of the Pathology Units of the following medical
      centers in Venezuela: Instituto de Oncología Luis Razetti, Anatomía Patológica Universidad
      Central de Venezuela, Hospital Oncológico Pérez Carreño (Valencia), Maracaibo, Barquisimeto,
      Ciudad Bolívar, Puerto La Cruz, Mérida and Barinas.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        cervical samples
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        paraffin blocks of 329 patients with histologic diagnosis of CIN 2, CIN 3 or Stage I
        cervical cancer. -

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge sanchez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Oncologico Luis Razetti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Oncologico Luis razetti</name>
      <address>
        <city>Caracas</city>
        <state>DF</state>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jorge Sanchez Lander</name>
      <address>
        <city>Caracas</city>
        <state>Miranda</state>
        <zip>1060</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <link>
    <url>http://www.cancerepidemiology.net/article/S1877-7821(12)00058-6/abstract</url>
    <description>Cancer epidemiology 36 (2012):e284-e287</description>
  </link>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <results_first_submitted>June 6, 2012</results_first_submitted>
  <results_first_submitted_qc>October 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2012</results_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Oncologico Luis Razetti</investigator_affiliation>
    <investigator_full_name>Dr. Jorge Sanchez Lander</investigator_full_name>
    <investigator_title>Dr. Jorge Sanchez-Lander</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>Human Papillomavirus Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Samples were collected from files between 2001-2011</recruitment_details>
      <pre_assignment_details>14 samples were excluded because of misdiagnosis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Invasive Cervical Cancer</title>
          <description>patients with histologic diagnosis invasive cervical cancer.</description>
        </group>
        <group group_id="P2">
          <title>Cervical Intraepithelial Neoplasia 2</title>
          <description>patients with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
        </group>
        <group group_id="P3">
          <title>Cervical Intraepithelial Neoplasia 3</title>
          <description>patients with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Histological Samples</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>misdiagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Invasive Cervical Cancer</title>
          <description>Paraffin-embedded samples with histological diagnosis of invasive cervical cancer</description>
        </group>
        <group group_id="B2">
          <title>Intraepithelial Cervical Neoplasia 3</title>
          <description>Paraffin-embedded samples with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
        </group>
        <group group_id="B3">
          <title>Intraepithelial Cervical Neoplasia 2</title>
          <description>Paraffin-embedded samples with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="329"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="12.04"/>
                    <measurement group_id="B2" value="37.6" spread="10.42"/>
                    <measurement group_id="B3" value="36.9" spread="9.34"/>
                    <measurement group_id="B4" value="39.27" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Venezuela</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HPV Identification</title>
        <description>HPV distribution was identified in CIN2, CIN3 and invasive cervical cancer</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Identification</title>
          <description>HPV distribution was identified in CIN2, CIN3 and invasive cervical cancer</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 16</title>
        <description>Number of biopsies positive to HPV 16.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 16</title>
          <description>Number of biopsies positive to HPV 16.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 18</title>
        <description>Number of biopsies positive to HPV 18.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 18</title>
          <description>Number of biopsies positive to HPV 18.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 31</title>
        <description>Number of biopsies positive to HPV 31.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 31</title>
          <description>Number of biopsies positive to HPV 31.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 33</title>
        <description>Number of biopsies positive to HPV 33.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 33</title>
          <description>Number of biopsies positive to HPV 33.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 45</title>
        <description>Number of biopsies positive to HPV 45.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 45</title>
          <description>Number of biopsies positive to HPV 45.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 58</title>
        <description>Number of biopsies positive to HPV 58.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 58</title>
          <description>Number of biopsies positive to HPV 58.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HPV Type 51</title>
        <description>Number of biopsies positive to HPV 51.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Invasive Cervical Cancer</title>
            <description>Paraffin-embedded sample with histological diagnosis of invasive cervical cancer</description>
          </group>
          <group group_id="O2">
            <title>Cervical Intraepithelial Neoplasia 3</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
          </group>
          <group group_id="O3">
            <title>Cervical Intraepithelial Neoplasia 2</title>
            <description>Paraffin-embedded sample with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
          </group>
        </group_list>
        <measure>
          <title>HPV Type 51</title>
          <description>Number of biopsies positive to HPV 51.</description>
          <units>biopsies</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="142"/>
                <count group_id="O3" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse event assessment because there were no patient intervention, there were used biopsies from archives for the analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Invasive Cervical Cancer</title>
          <description>Paraffin-embedded samples with histological diagnosis of invasive cervical cancer</description>
        </group>
        <group group_id="E2">
          <title>Intraepithelial Cervical Neoplasia 3</title>
          <description>Paraffin-embedded samples with histological diagnosis of cervical intraepithelial neoplasia grade 3</description>
        </group>
        <group group_id="E3">
          <title>Intraepithelial Cervical Neoplasia 2</title>
          <description>Paraffin-embedded samples with histological diagnosis of cervical intraepithelial neoplasia grade 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jorge Sánchez-Lander Corresponding Author</name_or_title>
      <organization>Instituto de Oncología Dr. Luis Razetti, Caracas Venezuela</organization>
      <phone>582129870165</phone>
      <email>animamotrix@live.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

